AstraZeneca CEO Pascal Soriot said the $37 billion pharmaceutical company is unsure of its future in vaccines and expects slower drug rollouts due to the Inflation Reduction Act, according to an exclusive interview with Reuters Aug. 23.
Read the full post on Becker's Hospital Review - Healthcare News
